We are live on ! Find out more
ACUR

Acura Pharmaceuticals
ACUR

Delisted

ACUR was delisted on the 22nd of February, 2017.

Back to rankings

22 hedge funds and large institutions have $2.69M invested in Acura Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less funds holding

Funds holding: 24 → 22 (-2)

55% less capital invested

Capital invested by funds: $5.94M → $2.69M (-$3.24M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.55%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
5
Reduced
2
Closed
3
Calls
$20K
Puts
–
Net Calls
+$20K
Net Calls Change
-$27K

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$46.6K
2
Renaissance Technologies
Renaissance Technologies
New York
+$32.7K
3
BFA
BlackRock Fund Advisors
California
+$2.26K
4
Morgan Stanley
Morgan Stanley
New York
+$418
5
Northern Trust
Northern Trust
Illinois
+$113

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$261K
2
Citadel Advisors
Citadel Advisors
Florida
-$49K
3
TRCT
Tower Research Capital (TRC)
New York
-$1K
4
Bank of America
Bank of America
North Carolina
-$889
Name Holding Trade Value Shares
Change 		Change in
Stake
EWM
1
Essex Woodlands Management
Texas
$1.51M – – –
DM
2
Deerfield Management
New York
$786K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$150K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$87K +$32.7K +31,300 +38%
SM
5
Sabby Management
Florida
$79K -$261K -249,391 -71%
VKH
6
Virtu KCG Holdings
New York
$34K +$46.6K +44,565 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$16K +$88 +84 +0.4%
FWP
8
FAS Wealth Partners
Kansas
$13K – – –
Northern Trust
9
Northern Trust
Illinois
$10K +$113 +108 +0.8%
BFA
10
BlackRock Fund Advisors
California
$8K +$2.26K +2,160 +26%
BA
11
BlackRock Advisors
Delaware
$2K – – –
AP
12
Atwood & Palmer
Missouri
$1K – – –
Group One Trading
13
Group One Trading
Illinois
$1K – – –
Morgan Stanley
14
Morgan Stanley
New York
$1K +$418 +400 +38%
Citadel Advisors
15
Citadel Advisors
Florida
– -$49K -30,483 Closed
Bank of America
16
Bank of America
North Carolina
– -$889 -850 -100%
TRCT
17
Tower Research Capital (TRC)
New York
– -$1K -747 Closed

ACUR Hedge Fund Activity: Q4 2016 in Review

22 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q4 2016, worth a combined $2.69M — down 55% from $5.94M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ACUR and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $46.6K. The largest seller was Sabby Management, cutting an estimated $261K.

  • 22 institutional investors held Acura Pharmaceuticals (ACUR) as of Q4 2016, down from 24 in Q3 2016.
  • Funds reported $2.69M of Acura Pharmaceuticals stock for Q4 2016, down 55% quarter-over-quarter.
  • 1 fund opened new Acura Pharmaceuticals positions in Q4 2016 and 3 closed out, a net change of -2 holders.
  • The largest Acura Pharmaceuticals buyer in Q4 2016 was Virtu KCG Holdings, an estimated $46.6K added.
  • The largest Acura Pharmaceuticals seller in Q4 2016 was Sabby Management, an estimated $261K sold.

Based on aggregated 13F filings for Q4 2016.